These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35904005)

  • 1. Understanding the suitability of established antibiotics for oral inhalation from a pharmacokinetic perspective: an integrated model-based investigation based on rifampicin, ciprofloxacin and tigecycline in vivo data.
    Himstedt A; Braun C; Wicha SG; Borghardt JM
    J Antimicrob Chemother; 2022 Oct; 77(11):2922-2932. PubMed ID: 35904005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
    Boger E; Fridén M
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption.
    Miller NA; Graves RH; Edwards CD; Amour A; Taylor E; Robb O; O'Brien B; Patel A; Harrell AW; Hessel EM
    Clin Pharmacokinet; 2022 Feb; 61(2):281-293. PubMed ID: 34458976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD004197. PubMed ID: 28440853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers.
    Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Kietzig C; Weimann B
    J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):53-63. PubMed ID: 27448179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
    Sadiq MW; Nielsen EI; Khachman D; Conil JM; Georges B; Houin G; Laffont CM; Karlsson MO; Friberg LE
    J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):69-79. PubMed ID: 27578330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Regional Respiratory Tissue and Systemic Concentrations of Orally Inhaled Drugs through a Novel PBPK Model.
    Ladumor MK; Unadkat JD
    Drug Metab Dispos; 2022 May; 50(5):519-528. PubMed ID: 35246463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.
    Stass H; Nagelschmitz J; Willmann S; Delesen H; Gupta A; Baumann S
    Clin Drug Investig; 2013 Jun; 33(6):419-27. PubMed ID: 23605507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mechanistic framework for a priori pharmacokinetic predictions of orally inhaled drugs.
    Hartung N; Borghardt JM
    PLoS Comput Biol; 2020 Dec; 16(12):e1008466. PubMed ID: 33320846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals.
    Berlin S; Kirschbaum A; Spieckermann L; Oswald S; Keiser M; Grube M; Venner M; Siegmund W
    Equine Vet J; 2017 Sep; 49(5):618-623. PubMed ID: 28063154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic modeling to establish the role of P-glycoprotein on ciprofloxacin distribution to lung and prostate following intravenous and intratracheal administration to Wistar rats.
    Zimmermann ES; de Miranda Silva C; Neris C; Torres BGDS; Schmidt S; Dalla Costa T
    Eur J Pharm Sci; 2019 Jan; 127():319-329. PubMed ID: 30423435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats.
    Khadka P; Sinha S; Tucker IG; Dummer J; Hill PC; Katare R; Das SC
    Eur J Pharm Biopharm; 2021 May; 162():1-11. PubMed ID: 33639255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model Calculations of Regional Deposition and Disposition for Single Doses of Inhaled Liposomal and Dry Powder Ciprofloxacin.
    Martin AR; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):49-60. PubMed ID: 28708440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically-Based Pharmacokinetic model for Ciprofloxacin in children with complicated Urinary Tract Infection.
    Balbas-Martinez V; Michelet R; Edginton AN; Meesters K; Trocóniz IF; Vermeulen A
    Eur J Pharm Sci; 2019 Feb; 128():171-179. PubMed ID: 30503378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the anticoagulant ethylenediamine tetra-acetic acid (EDTA) on the estimation of pharmacokinetic parameters: A case study with tigecycline and ciprofloxacin.
    Chen Q; Tung EC; Ciccotto SL; Strauss JR; Ortiga R; Ramsay KA; Tang W
    Xenobiotica; 2008 Jan; 38(1):76-86. PubMed ID: 17963190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.
    Borghardt JM; Weber B; Staab A; Kloft C
    AAPS J; 2015 Jul; 17(4):853-70. PubMed ID: 25845315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.